Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
15/05/2026 11:15
May 15 (Reuters) - Tenaya Therapeutics Inc TNYA.O: POSITIVE INTERIM DATA FROM COHORTS 1 AND 2 OF TENAYA’S RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 DEMONSTRATED CONSISTENT REDUCTIONS IN ARRHYTHMIA BURDEN FOR ADULTS WITH PKP2-ASSOCIATED ARVC TENAYA THERAPEUTICS INC - ALL PATIENTS ACHIEVE MEAN 64% DECREASE IN DAILY PVC COUNT WITH TN-401 TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG AND 6E13 VG/KG DOSES TENAYA THERAPEUTICS INC - TN-401 ADVERSE EVENTS WERE ASYMPTOMATIC AND SELF-RESOLVED OR RESPONDED TO TREATMENT Source text: ID:nGNX5fYMBw Further company coverage: TNYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027